Changes in exercise endurance and inspiratory capacity after lumacaftor/ivacaftor therapy in cystic fibrosis

Affiliations

• ¹ Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy. Electronic address: daniela.savi@uniroma1.it.
• ² Department of Pathophysiology and Transplantation, University of Milan, Italy; Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Italy. Electronic address: gramegna.med@gmail.com.
• ³ Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Internal Medicine Department, Cardiovascular Disease, University of Milan, Milan, Italy; Dyspnea Lab, Department of Clinical Sciences and Communty Health, University of Milan, Italy. Electronic address: marco.vicenzi@unimi.it.
• ⁴ Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy. Electronic address: marcello.dipaolo@uniroma1.it.
• ⁵ Adult Cystic Fibrosis Center, Pulmonology Dept, Azienda Ospedaliera Universitaria San Luigi Gonzaga, 10043 Orbassano, Italy. Electronic address: barbara.messore@gmail.com.
• ⁶ Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Rome, Italy. Electronic address: paolo.palange@uniroma1.it.
• ⁷ Department of Pathophysiology and Transplantation, University of Milan, Italy; Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano, Italy. Electronic address: francesco.blasi@unimi.it.